Background Care quality indicators are used to quantify quality of care. The Spanish HIV group (GESIDA) has developed care quality indicators for the care of persons infected by HIV/AIDS, some of them related to pharmaceutical activities.
Purpose To determine the compliance with GESIDA indicators and identify areas in which to improve HIV pharmaceutical care.
Material and methods Prospective multicentre study. Inclusion criteria: treatment-naïve patients beginning antiretroviral therapy in 2012 and 2013, 48 weeks of treatment and patient monitoring in pharmaceutical care consultations of the centres involved (PSITAR cohort). The care quality indicators were obtained from the GESIDA consensus document/National AIDS Plan on antiretroviral treatment in adults (2014).
Results 102 patients were studied, 86.3% male, mean age of 39.4 years (SD 11.79). At the beginning of the treatment the median viral load was 69,700 and mean CD4 was 316 (SD 216); in 57% of patients it was <350. 5.8% of patients showed resistance to any treatment. The most common treatments were tenofovir, emtricitabine and efavirenz combination (44%), darunavir, ritonavir, tenofovir, and emtricitabine combination (10%) and tenofovir, emtricitabine and raltegravir combination (8%).
Conclusion Effectiveness, efficiency and safety care quality indicators are mostly achieved. We can conclude that more resistance studies are required in the event of virological failure and we should improve treatment adherence records.
References and/or Acknowledgements
References and/or AcknowledgementsNo conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.